Watch CNBC's exclusive interview with Dexcom CEO Jake Leach

Watch on YouTube ↗  |  January 13, 2026 at 22:24  |  4:24  |  CNBC
Speakers
Jake Leach — President and Chief Executive Officer, DexCom, Inc.

Summary

Dexcom CEO Jake Leach tells CNBC's Closing Bell Overtime that the company is guiding to significant growth and that the CGM category remains highly underpenetrated, with only 2% of diabetics using it. He argues GLP-1 drugs are complementary rather than a headwind, citing improved adherence and glucose feedback. Leach also highlights expanded reimbursement to all diabetics, 9 million covered U.S. non-users, and international access opening in Western Europe and Asia Pacific, with Dexcom exiting 2025 at 3.5 million users, up over 20%.

  • Dexcom CEO discusses 2026 outlook and significant growth guidance.
  • CGM remains only 2% penetrated among people with diabetes.
  • GLP-1 drugs are described as complementary to CGM, not a growth offset.
  • Reimbursement expanded to all diabetics; 9 million covered U.S. patients are non-users.
  • International access is expanding in Western Europe and Asia Pacific.
  • Dexcom exited 2025 with 3.5 million users, over 20% growth, and record new patients.
Ideas
Jake Leach President and Chief Executive Officer, DexCom, Inc. 0:35
Dexcom guides significant growth; users up 20%
Jake Leach says Dexcom is guiding to significant growth as CGM remains highly underpenetrated at only 2% of diabetics, GLP-1s are complementary rather than a headwind, reimbursement expanded last year to cover all people with diabetes and should keep growing, 9 million covered U.S. patients are not yet using CGM, and international access is opening in Western Europe and Asia Pacific; Dexcom exited 2025 with 3.5 million users, up over 20% year over year, with record new patients.
DXCM HIGH
Jake Leach President and Chief Executive Officer, DexCom, Inc. 1:42
CGM is underpenetrated; GLP-1s are complementary
Leach says CGM has been one of the fastest-growing medtech categories for the past decade, but only 2% of diabetics use it; GLP-1 drugs are complementary because CGM gives immediate feedback and shows GLP-1 benefits, improving adherence, and reimbursement is expanding to all diabetics with 9 million covered U.S. non-users and international access opening in Western Europe and Asia Pacific.
Continuous glucose monitoring (CGM) HIGH
Up Next
7:41
UBS’ Fang on China Markets, Investment Strategy
Bloomberg Markets · Jan 13
4:07
Citi's Rob Sockin: While still high, inflation is coming in better than we would have expected
CNBC · Jan 13
41:38
[26.01.14.시황] 파월이 정의, 트럼프는 불의?…AI 관련주는 계속 갑니다 [월가 뉴스레터]
3PRO TV (삼프로TV) · Jan 13
38:58
Explained: Donald Trump vs Jerome Powell
Anthony Pompliano · Jan 13
4:45
Corporate America's Playbook for Dealing With Trump
Bloomberg Markets · Jan 13

This CNBC video, published January 13, 2026, features Jake Leach discussing DXCM, Continuous glucose monitoring (CGM). 2 trade ideas extracted by AI with direction and confidence scoring.

Speakers: Jake Leach  · Tickers: DXCM, Continuous glucose monitoring (CGM)